Literature DB >> 22941973

Characteristics of TBS-extractable hyperphosphorylated tau species: aggregation intermediates in rTg4510 mouse brain.

Naruhiko Sahara1, Michael DeTure, Yan Ren, Abdul-Shukkur Ebrahim, Dongcheul Kang, Joshua Knight, Christiane Volbracht, Jan Torleif Pedersen, Dennis W Dickson, Shu-Hui Yen, Jada Lewis.   

Abstract

Conditional overexpression of four-repeat human tau containing the P301L missense mutation in the rTg4510 mouse model of tauopathy leads to progressive accumulation of neurofibrillary tangles and hyperphosphorylated, sarkosyl-insoluble tau species, which are biochemically comparable to abnormal tau characteristic of hereditary tauopathies termed FTDP-17. To fully understand the impact of tau species at different stages of self-assembly on neurodegeneration, we fractionated rTg4510 brain representing several stages of tauopathy to obtain TBS-extractable (S1), high salt/sarkosyl-extractable (S3), and sarkosyl-insoluble (P3) fractions. Under reducing condition, the S1 fraction was demonstrated by western blotting to contain both 50-60 kDa normally-sized and 64 kDa tau. Both are thermo-stable, but the 64 kDa tau showed a higher degree of phosphorylation. Under non-reducing condition, nearly all TBS-extractable 64 kDa tau were detected as ∼130 kDa species consistent with the size of dimer. Quantitative analysis showed ∼80 times more 64 kDa tau in S1 than P3 fraction. Immunoelectron microscopy revealed tau-positive granules/short filaments in S1 fraction. These structures displayed MC1 immunoreactivities indicative of conformational/pathological change of tau. MC1 immunoreactivity was detected by dot blotting in samples from 2.5 month-old mice, whereas Ab39 immunoreactivity indicative of late stages of tau assembly was detected only in P3 fraction. Quantitative analysis also demonstrated a significant inverse correlation between brain weight and 64 kDa tau, but the level of TBS-extractable 64 kDa tau reflects neurodegeneration better than that of sarkosyl-insoluble 64 kDa tau. Together, the findings suggest that TBS-extractable 64 kDa tau production is a potential target for therapeutic intervention of tauopathies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22941973      PMCID: PMC3514650          DOI: 10.3233/JAD-2012-121093

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  39 in total

Review 1.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

2.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein.

Authors:  J Lewis; E McGowan; J Rockwood; H Melrose; P Nacharaju; M Van Slegtenhorst; K Gwinn-Hardy; M Paul Murphy; M Baker; X Yu; K Duff; J Hardy; A Corral; W L Lin; S H Yen; D W Dickson; P Davies; M Hutton
Journal:  Nat Genet       Date:  2000-08       Impact factor: 38.330

3.  Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein.

Authors:  Bridget Allen; Esther Ingram; Masaki Takao; Michael J Smith; Ross Jakes; Kanwar Virdee; Hirotaka Yoshida; Max Holzer; Molly Craxton; Piers C Emson; Cristiana Atzori; Antonio Migheli; R Anthony Crowther; Bernardino Ghetti; Maria Grazia Spillantini; Michel Goedert
Journal:  J Neurosci       Date:  2002-11-01       Impact factor: 6.167

4.  Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility.

Authors:  Naruhiko Sahara; Jada Lewis; Michael DeTure; Eileen McGowan; Dennis W Dickson; Mike Hutton; Shu-Hui Yen
Journal:  J Neurochem       Date:  2002-12       Impact factor: 5.372

5.  Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles.

Authors:  C W Wittmann; M F Wszolek; J M Shulman; P M Salvaterra; J Lewis; M Hutton; M B Feany
Journal:  Science       Date:  2001-06-14       Impact factor: 47.728

6.  Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease.

Authors:  Kristina R Patterson; Christine Remmers; Yifan Fu; Sarah Brooker; Nicholas M Kanaan; Laurel Vana; Sarah Ward; Juan F Reyes; Keith Philibert; Marc J Glucksman; Lester I Binder
Journal:  J Biol Chem       Date:  2011-05-06       Impact factor: 5.157

7.  Memory and mental status correlates of modified Braak staging.

Authors:  E Grober; D Dickson; M J Sliwinski; H Buschke; M Katz; H Crystal; R B Lipton
Journal:  Neurobiol Aging       Date:  1999 Nov-Dec       Impact factor: 4.673

8.  Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments.

Authors:  A Alonso ; T Zaidi; M Novak; I Grundke-Iqbal; K Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-29       Impact factor: 11.205

9.  Conformational change as one of the earliest alterations of tau in Alzheimer's disease.

Authors:  C L Weaver; M Espinoza; Y Kress; P Davies
Journal:  Neurobiol Aging       Date:  2000 Sep-Oct       Impact factor: 4.673

10.  Tau filament formation in transgenic mice expressing P301L tau.

Authors:  J Götz; F Chen; R Barmettler; R M Nitsch
Journal:  J Biol Chem       Date:  2001-01-05       Impact factor: 5.157

View more
  52 in total

1.  Nasal vaccine delivery attenuates brain pathology and cognitive impairment in tauopathy model mice.

Authors:  Hiroki Takeuchi; Keiko Imamura; Bin Ji; Kayoko Tsukita; Takako Enami; Keizo Takao; Tsuyoshi Miyakawa; Masato Hasegawa; Naruhiko Sahara; Nobuhisa Iwata; Makoto Inoue; Hideo Hara; Takeshi Tabira; Maiko Ono; John Q Trojanowski; Virginia M-Y Lee; Ryosuke Takahashi; Tetsuya Suhara; Makoto Higuchi; Haruhisa Inoue
Journal:  NPJ Vaccines       Date:  2020-03-25       Impact factor: 7.344

2.  TOC1: a valuable tool in assessing disease progression in the rTg4510 mouse model of tauopathy.

Authors:  Sarah M Ward; Diana S Himmelstein; Yan Ren; Yifan Fu; Xiao-Wen Yu; Kaleigh Roberts; Lester I Binder; Naruhiko Sahara
Journal:  Neurobiol Dis       Date:  2014-03-12       Impact factor: 5.996

3.  Pseudophosphorylation of tau at S422 enhances SDS-stable dimer formation and impairs both anterograde and retrograde fast axonal transport.

Authors:  Chelsea T Tiernan; Benjamin Combs; Kristine Cox; Gerardo Morfini; Scott T Brady; Scott E Counts; Nicholas M Kanaan
Journal:  Exp Neurol       Date:  2016-06-30       Impact factor: 5.330

4.  Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease.

Authors:  Jesper Riise; Niels Plath; Bente Pakkenberg; Anna Parachikova
Journal:  J Neural Transm (Vienna)       Date:  2015-02-14       Impact factor: 3.575

5.  Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species.

Authors:  Mirta Boban; Mirjana Babić Leko; Terezija Miškić; Patrick R Hof; Goran Šimić
Journal:  J Neurosci Methods       Date:  2018-09-29       Impact factor: 2.390

6.  Analysis of isoform-specific tau aggregates suggests a common toxic mechanism involving similar pathological conformations and axonal transport inhibition.

Authors:  Kristine Cox; Benjamin Combs; Brenda Abdelmesih; Gerardo Morfini; Scott T Brady; Nicholas M Kanaan
Journal:  Neurobiol Aging       Date:  2016-07-29       Impact factor: 4.673

7.  Tau Oligomer Pathology in Nucleus Basalis Neurons During the Progression of Alzheimer Disease.

Authors:  Chelsea T Tiernan; Elliott J Mufson; Nicholas M Kanaan; Scott E Counts
Journal:  J Neuropathol Exp Neurol       Date:  2018-03-01       Impact factor: 3.685

Review 8.  Potential mechanisms and implications for the formation of tau oligomeric strains.

Authors:  Julia E Gerson; Amrit Mudher; Rakez Kayed
Journal:  Crit Rev Biochem Mol Biol       Date:  2016-09-21       Impact factor: 8.250

9.  Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau P301L mice.

Authors:  Mala V Rao; Mary Kate McBrayer; Jabbar Campbell; Asok Kumar; Audrey Hashim; Henry Sershen; Philip H Stavrides; Masuo Ohno; Michael Hutton; Ralph A Nixon
Journal:  J Neurosci       Date:  2014-07-09       Impact factor: 6.167

10.  Thiol-mediated and catecholamine-enhanced multimerization of a cerebrovascular disease enriched fragment of NOTCH3.

Authors:  Kelly Z Young; Naw May P Cartee; Magdalena I Ivanova; Michael M Wang
Journal:  Exp Neurol       Date:  2020-02-28       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.